Skip Nav Destination
![]()
You do not currently have access to this content.
Live Bacterial Supplementation May Enhance Therapy Effectiveness in Metastatic RCC Available to Purchase
July 16, 2024
Major Finding: Supplementation with CBM588, a live bacterial product that stimulates growth of bifidobacteria, was associated with better response to cabozantinib plus nivolumab in metastatic RCC.
Concept: The relative abundance or diversity of Bifidobacterium species was not affected by supplementation with CBM588.
Impact: Further investigation into the activity and mechanism of action of CBM588 in this therapeutic setting is warranted.
RSS Feeds
